Hemophagocytic Lymphohistiocytosis: an Unusual Complication of Orientia tsutsugamushi Disease (Scrub Typhus)

Aneesh Basheer, Somanath Padhi, Vinoth Boopathy, Saumyaranjan Mallick, Shashikala Nair, Renu G’Boy Varghese, and Reba Kanungo

Departments of 1General Medicine, 2Pathology, 3Gastroenterology, and 5Microbiology, Pondicherry Institute of Medical Sciences, Puducherry, India.

4Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

Abstract. Background: Hemophagocytic lymphohistiocytosis (HLH) is an uncommon, potentially fatal, hyperinflammatory syndrome that may rarely complicate the clinical course of Orientia tsutsugamushi disease (scrub typhus).

Methods: Here we describe the clinicopathological features, laboratory parameters, management, and outcome of three adult patients (1 female, 2 males) with scrub typhus associated HLH from a tertiary center. A brief and concise review of international literature on the topic was also added.

Results: All three patients satisfied the HLH-2004 diagnostic criteria; one had multi-organ dysfunction with very high ferritin level (>30,000 ng/ml), and all had a dramatic recovery following doxycyclin therapy. Literature review from January 1990 to March 2014 revealed that scrub typhus associated HLH were reported in 21 patients, mostly from the scrub endemic countries of the world. These included 11 females and 10 males with a mean age of 35 years (range; 8 months to 81 years). Fifteen of 17 patients (where data were available) had a favorable outcome following early serological diagnosis and initiation of definitive antibiotic therapy with (N=6) or without (N=9) immunosuppressive/immunomodulator therapy. Mutation analysis for primary HLH was performed in one patient only, and HLH-2004 protocol was used in two patients.

Conclusion: We suggest that HLH should be considered in severe cases of scrub typhus especially if associated with cytopenia (s), liver dysfunction, and coagulation abnormalities. Further studies are required to understand whether an immunosuppressive and/or immunomodulator therapy could be beneficial in those patients who remain unresponsive to definitive antibiotic therapy.

Citation: Basheer A, Padhi S, Boopathy V, Mallick S, Nair S, Varghese RG, Kanungo R. Hemophagocytic Lymphohistiocytosis: an Unusual Complication of Orientia tsutsugamushi Disease (Scrub Typhus). Mediterr J Hematol Infect Dis 2015, 7(1): e2015008, DOI: http://dx.doi.org/10.4084/MJHID.2015.008

Published: 2015 Received: September 6, 2014 Accepted: November 28, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Dr. Somanath Padhi, M.D., Associate Professor, Department of Pathology, Pondicherry Institute of Medical Sciences, Puducherry, India, 605014. Tel: 91-413-2625275, Fax: 91-413-2625273. E-mail: somanath.padhi@gmail.com

Introduction. Hemophagocytic lymphohistiocytosis (HLH) is a syndrome, often fatal, of exacerbated but ineffective inflammatory response, characterized by excessive macrophage and T-cell activation as well as impairment of the ability of natural killer (NK) cell and cytotoxic T lymphocytes to kill the target cells. This results in uncontrolled histiocytic phagocytosis of mature blood elements and their precursors throughout the reticuloendothelial organs; and associated cytokine-mediated multiorgan dysfunction. Primary or familial
HLH appears to have a genetic basis, whereas secondary or acquired HLH may be associated with infections (commonly Epstein Barr Virus, bacteria, Rickettsia, etc), hematological malignancies (mostly T/NK cell leukemias/lymphomas), rheumatological/autoimmune disorders (so-called macrophage activation syndrome), etc.\(^3\)\(^5\) The diagnosis is established by fulfilling one of the following HLH-2004 criteria: i) positive family history or molecular diagnosis consistent with HLH (mutations of PRF, SAP, or MUNC13-4 genes), ii) any five out of the following eight criteria; prolonged fever, unexplained progressive cytopenias involving at least 2 cell lines (hemoglobin ≤ 90 g/L, platelet count ≤ 100 x 10\(^9\)/L, absolute neutrophil count < 1 x 10\(^9\)/L), splenomegaly, hyperferritinemia (≥ 500 ng/mL), fasting hypertriglyceridemia (≥ 265 mg/dL) or hypofibrinogenemia (≤ 1.5 g/L), histiocytic hemophagocytosis in bone marrow, liver, spleen, or lymph nodes without evidence of malignancy, low or absent NK cell cytotoxicity, and elevated soluble CD25 levels (≥ 2400 IU/mL of interleukin-2Rα chain).\(^6\)

In this manuscript, we describe three adult patients with scrub typhus associated HLH from a tertiary care center in South India. We also present a brief concise review of international literature regarding scrub typhus associated HLH in relation to the clinicopathological characteristics, immunopathology, and therapeutic outcome.

Material and Methods.

**Present case descriptions:** The clinicopathological features, laboratory data, and therapeutic outcome of all three patients (1 female, aged 19 years; and 2 males, aged 64, 45 years) are presented in Table 1. All the three required admission into intensive care unit. They had prolonged fever (that ranged from 10 days to 2 months duration) and generalized signs, and symptoms suggestive of systemic inflammatory response syndrome (SIRS), which were presumptively managed as sepsis. All three developed tachypnea, bilateral coarse crepitations and hypoxemia. Clinical, laboratory, and radiological features were consistent with acute respiratory distress syndrome (ARDS), which required ventilator support. In addition, two of the patients (cases 1 & 2) also developed acute kidney injury; all three had jaundice with elevated liver transaminases with deranged coagulation parameters in the form of prolonged prothrombin time (PT) and/or activated partial thromboplastin time (APTT); and one patient (case 1) progressed to disseminated intravascular coagulation (DIC) [increased fibrin degradation product, D-dimer + (qualitative)], possibly secondary to severe sepsis. Physical examination revealed conjunctival pallor and hepatosplenomegaly in all; whereas lymphadenopathy (cervical and axillary) and an eschar (over left groin) were noted in one patient (case 3).

Microbiological and serological work-up was negative for HIV, hepatitis B and C viruses, dengue, malaria, leptospirosis, brucella, and Epstein-Barr virus. Microbial cultures of blood, urine, sputum, bronchoalveolar lavage fluid, and bone marrow aspirate were sterile. A diagnosis of scrub typhus was confirmed by presence of IgM antibody against Orientia tsutsugamushi (O. tsutsugamushi) by ELISA. All underwent single bone marrow procedure due to persistent bi/pancytopenia, fever, and organomegaly; that revealed histiocytic hemophagocytosis (marked in case 1, mild in cases 2 & 3). The assessment of histiocytic hemophagocytosis on bone marrow aspirate smears was done as per the method devised by Ho et al (low/mild; 1-5 hemophagocytic cells per entire slide, moderate; 6-10 hemophagocytic cell per entire slide; > 10 hemophagocytic cell per entire slide).\(^7\) Furthermore, all three had hyperferritinemia (>1000 ng/mL) [a “sky high” level of >30,000 ng/mL in case 1] and elevated lactate dehydrogenase (>500 IU/L); and two (cases 1 & 2) had hypertriglyceridemia (>265 mg/dL), hypoalbuminemia (<2.5 g/dL), and hyponatremia (≤ 125 meq/L). All patients fulfilled five of six HLH-2004 diagnostic criteria, as NK cell activity and soluble CD25 levels were not tested due to lack of facility, and none of the patients were subjected to genetic testing for the diagnosis of primary HLH.

All 3 patients were empirically treated with broad-spectrum intravenous antibiotics and supportive measures. Following confirmation of scrub typhus by IgM ELISA, oral doxycyclin (100 mg twice daily) was started. Furthermore, case 1 was started on intravenous corticosteroids and vasopressor drugs. Over a period of one week, the patients responded positively to the treatment, with abatement of fever, resolution of acute kidney injury, and hepatic dysfunction with correction of coagulopathy. Considering the very high ferritin level and clinical scenario in case 1, hematologist’s opinion was sought for commencing HLH-2004 protocol. After resolution of multi-organ dysfunction (MOD), etoposide was added to the ongoing regimen and was later withdrawn after full recovery of clinical and hematological parameters. At present this patient is under regular follow-up without any medications. The other two patients did not receive any specific immunosuppressive therapy for HLH and improved following treatment with oral doxycyclin.

**Review of International Literature.** A systematic search of HLH that complicated the course of scrub typhus over last 24 years (January 1990 to March 2014) was done by the search engine of PubMed, PubMed Central, Medline, and Directory of Open Access Journal databases. The following terminologies were used in the data search: hemophagocytic lymphohistiocytosis/hemophagocytosis/erythrophagocytosis over last 24 years (January 1990 to March 2014) was done by the search engine of PubMed, PubMed Central, Medline, and Directory of Open Access Journal databases. The following terminologies were used in the data search: hemophagocytic lymphohistiocytosis/hemophagocytosis/erythrophagocytosis/
Table 1. Clinicopathological characteristics and outcome data of 3 adult patients with scrub typhus associated hemophagocytic lymphohistiocytosis (HLH) diagnosed as per HLH-2004 criteria.6

| Patient characteristics | Case 1 | Case 2 | Case 3 |
|-------------------------|--------|--------|--------|
| Age (years)/gender      | 19, female | 64, male | 45, male |
| Presumptive diagnosis   | ?Sepsis | Sepsis, MODS | Sepsis |
| HLH-2004 criteria       |        |        |        |
| Fever                   | + (3 weeks) | + (10 days) | + (15 days), eschar+ |
| Splenomegaly ± hepatomegaly | + | + | + |
| Cytopenia (≥ 2 cell lines) | + | + | + |
| • Hemoglobin ≤ 90g/L     | + (66 g/L) | + (70) | + (69) |
| • Plateletcount ≤ 100 x 10⁹/L | + (80 x 10⁹/L) | + (76) | + (10) |
| • Absolute neutrophilcount (<1000/L) | + (675) | - (3700) | + (250) |
| Fasting serum triglyceride (> 265 mg/dL) | + (760) | + (399) | not tested |
| Hypofibrinogenemia (<150 mg/L) | not tested at diagnosis | not tested | not tested |
| Hyperferritinemia (> 500 ng/ml) | + (>30,000) | + (1354) | (>2000) |
| Hemophagocytosis in bone marrow [7] | mild-moderate | mild-moderate | mild-moderate |
| Natural Killer cell activity | marked | not done | not done |
| Soluble CD25             | not done | not done | not done |
| Molecular testing        | not done | not done | not done |
| Liver transaminases (≥ 200IU/L) | + | + (240/90) | WNL |
| Hyperbilirubinemia (mg/dL) (TB/DB) | + (22.5/17.5) | + (97.9) | + (45/3.9) |
| Prolonged PT ± aPTT (seconds) | + (55/90) | + (<50.4) | + (45/76) |
| Lactatedehydrogenase (IU/L) | 3000 | 760 | 530 |
| Hypoalbuminemia (< 3.5 g/dL) | + (2.5) | + (2.2) | - |
| Hyponatremia (< 135 meq/L) | + (126) | + (122) | - |
| D-dimer (semi-quantitative) and FDP | strongly positive | not done | + |
| Antinucleoantibody       | - | not done | not done |
| Procalcitonin (ng/dL)    | + (>100) | not done | not done |
| Etiology screen          | Orientia tsutsugamushi (IgM ELISA). | Orientia tsutsugamushi (IgM ELISA) | Orientia tsutsugamushi (IgM ELISA) |
| Management               | IV antibiotics, doxycyclin, ventilator support, vasopressor, steroids, etoposide | Doxycyclin | Doxycyclin |
| Outcome                  | Alive, on follow-up, 12 months | Cured and discharged | Cured and discharged |

Abbreviations: MODS; multiorgan dysfunction syndrome, +; present, WNL; within normal limits, TB/DB; total bilirubin/direct bilirubin, -; not present, FDP; fibrin degradation product, IV; intravenous.
ytosis/ macrophage activation syndrome and scrub typhus/Orientia tsutsugamushi/tsutsugamushi disease/Rickettsial disease; and references of all articles were cross-checked for relevant articles. Review showed 18 papers describing 21 cases of scrub typhus associated HLH around the world. Cascio et al, in 2011, reported a case of HLH (negative for perforsin 1, MUNC 13-4, SYNTAXIN 11 mutations) in a 5 year old Italian male child secondary to Rickettsia conorii (Mediterranean Spotted Fever, MSF); and reviewed another 16 cases of rickettsial associated HLH till that year [7 due to scrub typhus, 5 due to MSF, and 4 due to human monocytic ehrlichiosis (HME)]. In 4 of 21 cases of scrub typhus (2 from Taiwan, two from Japan), complete articles were not fully accessible for study. Clinical and laboratory data available have been put in a tabular format (Table 2).

Result and Discussion. Scrub typhus, also known as tsutsugamushi disease, is a chigger-borne zoonosis which is of great public health importance in tropical Asia and the islands of the Western Pacific Ocean. This infection or its etiologic agent (O. tsutsugamushi) has been documented within an endemic triangle with apices in the Primorje region of the Russian Far East, northern Australia, and Afghanistan. Scrub typhus is an acute febrile illness which results from the bite of infected larval form of mite, called chigger, in endemic areas. Following an incubation period of 7 to 10 days, the nonspecific prodrome of pyrexia, skin rash, myalgia, gastrointestinal disturbances, and lymphadenopathy starts. Although not consistently seen, the most pathognomonic sign of scrub typhus is an eschar that develops at the site of mite bite. During human infection, O. tsutsugamushi, being a rickettsial organism, selectively targets the vascular endothelial cells of the small to medium-sized blood vessels. However, it can also invade underlying tissues such as smooth muscle cells, perivascular macrophages, and monocytes. Consequently, widespread vasculitis/perivasculitis is the hallmark pathophysiologic mechanism implicated in multiorgan dysfunction syndrome (MODS) in patients with severe infections.

The main pathophysiologic characteristic of HLH is exacerbated but deregulated Th2 cell-mediated immune response against an intracellular pathogen, macrophage hyperactivity, widespread hemophagocytosis, and hypercytokinemia leading to multi-organ dysfunction. This results due to impaired or suppressed function of cytotoxic T cells and NK cells to effectively clear the antigenic stimulus and thus turn off the inflammatory response. The severity of rickettsial diseases varies with the causative organism and the host. Some rickettsial species such as Rickettsia rickettsii, Rickettsia prowazekii, and O. tsutsugamushi often cause more severe disease. Host factors like old age, alcoholism, diabetes mellitus, liver and respiratory diseases, and glucose-6-phosphate dehydrogenase deficiency have been associated with more severe disease. Experimental studies have shown that human cells are capable of controlling rickettsial infections intracellularly, by one or combination of three mechanisms involving nitric oxide synthesis, hydrogen peroxide production, and tryptophan degradation. These mechanisms involve a complex interaction of CD4+ and CD8+ T lymphocytes, macrophages, NK cells, B lymphocytes, antibodies, and cytokines. Inflammatory responses of humans appear to coincide with the disease severity in scrub typhus, and the cytotoxic T-cell mediated macrophage over activity may induce hemophagocytosis in susceptible individuals. This hypothesis has been further substantiated by the observation of increased serum levels of IFN-γ, M-CSF and TNF-α in patient with scrub typhus in several studies. A concise review on clinicopathological characteristics of all reported cases of scrub typhus associated HLH till March 2014 is presented in Table 2. There were 21 reported cases with HLH, complicating the course of scrub typhus (7 from India, 5 from China, 4 from Japan, 4 from South Korea, and 1 from Sri Lanka). These included 11 females and 10 males, with a mean age of 35 years (range: 8 months to 81 years); and none of these cases had obvious underlying co-morbidities. All patients, 18/18, in whom data were available, presented with acute febrile illness (mean duration: 10 days, range: 4 to 24 days); similarly all cases reported (14/14) had hepatosplenomegaly with or without regional lymphadenopathy. A characteristic eschar was signaled in 9/18 (50%) patients and seven of 18 (39%) had ARDS, 3 (16.7%) had neurological manifestations, 2 (11%) had acute renal failure, 2 (11%) had DIC with MODS, 2 (11%) had at onset acute hepatic failure. One had co-existent leptospirosis, and one had myocarditis, interstitial pneumonia, and reactivation of EBV infection. Eleven of 18 patients (61%), in whom data were available, had bicytopenia; 4/18 (22%) had pancytopenia, and 6/13 (37.5%) had coagulation abnormalities. Histiocytic hemophagocytosis was reported in bone marrow of all 16 examined patients (100%). Hemophagocytosis was of mild to moderate intensity in 14 (87.5%) patients whereas appeared marked in only two patients. This was reflected by modest elevation of serum ferritin level (N=13/21) (mean: 3320 ng/ml, range: 1415-15,000 ng/ml). Molecular analysis for primary HLH such as mutation of perforin and SYNTAXIN gene was performed in one patient (8 month male child) only. A recent study on pediatric HLH patients (N=38; 20 primary HLH, 18 secondary HLH) reported that hyperbiliarubinemia with cholestasis was highly suggestive of primary HLH; whereas high C-reactive protein levels was more in favor of a secondary HLH. The other parameters such as ferritin, triglyceride, PT, APTT were not statistically
| Age, gender, presentation | Fever (days) | Spleen | Hb, g/L | Plt, x10^9/L | ANC, /mm | Ferritin, ng/mL | TG, mg/dL | Fibrinogen, g/L | HP in BM | ALT/AST/LDH | Diagnostic method | Therapy, Outcome (days) | Place of reporting, year | [ref.] |
|--------------------------|-------------|--------|---------|-------------|----------|----------------|-----------|----------------|--------|-------------|---------------------|------------------------|--------------------------|-------|
| 40yrs, female, ARDS, seizure | Yes (10) | Yes | 77 | 15 | WNL | 4662 | 733 | ND | Present | 404/300/2140 | IgM ELISA (Leptospira), Weil-Felix | Dx + Mp; cured (14) | India, 2014 [8] |
| 20yrs, male, ARDS, ALF, eschar+ | Yes (14) | Yes | 97 | 200 | WNL | ND | ND | ND | BM | 150/265/601 | IgM ELISA (Leptospira), Weil-Felix | Dx, cured (15) | India, 2013 [9, 10] |
| 8 month, male child ARDS, CNS, DIC, eschar+ | Yes (10) | Yes | 71 | 78 | High | 7970 | 53 mg/dL, FDP, 36mcg/ml WNL | BM | notdone | 340/598/10,600 | IgM antibody (IHA test) | CI + Dex+ Ep, afebrile (4), cured (35) | South Korea, 2013 [11] |
| 5yrs, female child CNS, eschar & rash + | Yes (7) | Yes | 99 | 77 | 3000 | >7690 | WNL | ND | Moderate | 114/200/715 | IgM ELISA | HLH-2004 protocol, Dx, neurological impairment | South Korea, 2012 [12] |
| 7yrs, male child Myocarditis, interstitial pneumonia, liver dysfunction, Rash + | Yes (4) | Yes | 79 | 17 | 2240 | >1650 | 377 | Low | Present | 101/157/1193 | IgM, IgG, EBNA (EBV) IgM antibody (ICT) | Weil-Felix, IgM ELISA | Dx, cured (7) | India, 2011 [14] |
| 5yrs, female child, ARDS, ARF, Eschar & rash + | Yes (6) | Yes | 113 | 100 | 1000 | 4435 | 335 | Low | Mild | 114/156/NA | IgM ELISA | Weil-Felix, IgM ELISA | Supportive, antibiotics, death (35), | South Korea, 2010 [15] |
| 81yrs, female, MODS | Yes (NA) | Yes | 69 | 72 | 7300 | 1530 | NA | Low | Moderate | 112/91/2174 | IgM ELISA | Dx, cured (10) | India, 2014 [21] |
| 35yrs, male, ARDS Eschar + | Yes (10) | Yes | 70 | 13 | 1500 | 15000 | 250 | NA | Marked | 17998/NA | IgM ELISA | Dx, cured (10) | India, 2010 [16] |
| 61yrs, male, ARF | Yes (20) | Yes | 68 | 75 | 700 | 1500 | 226 | NA | Mild | 326/132/NA | IgM ELISA | Dx,cured (3) | India, 2010 [16] |
| 23yrs, male, non specific | Yes (5) | Yes | 120 | 47 | 1700 | 3700 | 265 | NA | Mild | 198/155/NA | IgM ELISA | Dx,cured (2) | India, 2010 [16] |
| 22yrs, male, FUO, rash | Yes (10) | Yes | 85 | 12 | 238 | >2000 | NA | NA | Mild | Weil-Felix | IgG ELISA (IF) | Dx, cured (2) | India, 2010 [17] |
| 58yrs, female, ARDS Eschar+ | Yes (24) | Yes | 65 | 56 | 782 | NA | WNL | WNL | NA | Moderate | 179/35/608 | IgM, IgG antibody (IF) | Weil-Felix, IgG antibody (IF) | D, cured (10) | Japan, 2001 [22] |
| 75yrs, female, FUO Eschar+ | Yes (NA) | NA | 128 | 14 | WNL | 183 | NA | NA | Moderate | 32/44/686 | IgM, IgG (IF) | D+ Ph, cured (25) | China, 2002 [21] |
| Eschar rash + | Yes (7) | NA | 113 | 75 | Low | 282 | NA | NA | Mild | 1735/608 | IgM, IgG antibody (IF) | Mn, cured (10) | China, 2002 [21] |
| Eschar rash + diarrohea Eschar rash + | Yes (7) | NA | 113 | 75 | Low | 282 | NA | NA | NA | NA | NA | NA | IgM anti R tsutsugamushi Gilliam antibody | D, cured (10) | Japan, 2001 [22] |
| Eschar rash + | Yes (7) | NA | 63 | Low | NA | NA | NA | NA | NA | NA | NA | NA | IgM anti R tsutsugamushi Gilliam antibody | D, cured (10) | Japan, 2001 [22] |
| 21yrs, male, FUO Eschar rash + | Yes (14) | Yes | 93 | 209 | Low (3000) | 1415 | 176 | NA | Moderate | 166/140/1555 | Weil-Felix (HA) | Dx,cured (14) | Taiwan, China, 2000 [23] |
| 53yrs, female, FUO Eschar + | Yes (7) | Yes | NA | 63 | Low | NA | NA | NA | Mild | NA/128/760 | IgM anti R tsutsugamushi Gilliam antibody | Mn, afebrile (3), cured (90) | Japan, 1994 [24] |
| 47yrs, female, ARDS | Yes (NA) | NA | NA | Low | NA | NA | NA | NA | Marked | NA | NA | NA | IgM anti R tsutsugamushi Gilliam antibody | Mn, afebrile (3), cured (90) | Japan, 1992 [25] |
| Present Series | Clinicopathological characteristics of hemophagocytic lymphohistiocytosis (HLH) in association with Orientia tsutsugamushi disease (Scrub typhus) (March 2014-January 1990) (N=18). |
|----------------|-------------------------------------------------------------------------------------------------|
| **Present Series** | **Clinical Features** | **Laboratory Findings** | **Therapy** | **Outcome** | **Location** |
| 19yr, female, Sepsis, MODS | Yes (21) | Yes | 66 | 80 | 675 | 30000 | 760 | - | Moderate | 300/350/3000 | IgM ELISA | Steroids, Dx, Ep, alive 12 months | Puducherry, India, 2012 |
| 47yr, male, FUO Eschar& rash + | Yes (15) | Yes | 69 | 10 | 250 | >2000 | - | low | Mild | -/-605/530 | IgM ELISA | Supportive, Dx | Puducherry, India, 2012 |
| 64yr, male, sepsis, MODS | Yes (10) | Yes | 70 | 76 | 1354 | 399 | - | Moderate | 240/90/760 | IgM ELISA | Dx, supportive, cured (15) | Puducherry, India, 2013 |

**Abbreviation:** ARDS: acute respiratory distress syndrome, ALF: acute liver failure, CNS: central nervous system, DIC: disseminated intravascular coagulation, ARF: acute renal failure, MODS: multiorgan dysfunction syndrome, FUO: fever of unknown origin, NA: not available, -: not present or not reported, +: present, Hb: hemoglobin, Plt: platelet count, ANC: absolute neutrophil count, WNL: within normal range, ND: not done/not tested, TG: serum triglyceride, FDP: fibrin degradation product, HP: hemophagocytosis, BM: bone marrow, ALT: alanine aminotransferase, AST: aspartate aminotransferase, LDH: lactate dehydrogenase, ICT: immunochromatography test, IHA: indirect haemagglutination, IF: immunofluorescence, R. tsutsugamushi: Rickettsia tsutsugamushi (now called as Orientia tsutsugamushi), Dx: doxycyclin, Mp: methylprednisolone, Cl: clarithromycin, Dexamethasone, Ep: etoposide, Pn: prednisolone, Mn: minocyclin. Note that in only one of 24 cases (including present series), genetic/mutation study was performed for primary HLH (Perforin/syntaxin mutation negative). Three cases from references where complete information was not available were not presented in the table.
Serological diagnosis of scrub typhus is usually possible after 5 to 10 days following onset of symptoms. Conventionally, Weil-Felix test based on heterophile antigen of Proteus vulgaris (OX-2, and OX-19) and Proteus mirabilis (OX-K) has been used widely. An agglutinating titer of >320 with OX-K is suggestive of scrub typhus. However, several Indian studies have shown a lower cut-off titer at ≥ 80 to indicate a possible infection with O. tsutsugamushi, thus making the test even more non-specific. Poor sensitivity and specificity of Weil-Felix is well established. Recently, IgM ELISA and IgM Capture ELISA techniques have shown better predictive value as diagnostic tests in scrub typhus. PCR-based tests have overcome the drawbacks of serological tests, in early detection using specific primers; and multiplex PCR has further improved diagnostic criteria in endemic areas. In all the reported cases of scrub typhus associated HLH, the diagnosis of rickettsial disease was serologically confirmed. The following serological methods were used for the diagnosis: Weil-Felix (N=5), IgM ELISA (N=6), IgM antibodies by indirect haemagglutination (IHA) (N=1), antibody titres by immunofluorescence (N=3), IgM antibody by immunochromatography (N=1), and IgM anti O. tsutsugamushi Gilliam antibody (N=1).

Scrub typhus responds more readily to antibiotics than other rickettsial diseases, with most patients becoming afebrile within 24 to 36 hours after beginning antibiotic therapy. A recent study by Japanese group had shown that age was an independent risk factor for mortality; furthermore patients with ≥ 2 days delay in treatment with tetracyclines had a significantly higher risk of complications compared to those without delay. In another study from South Korea, factors such as old age, presence of comorbidities, and high serum osteopontin (>100ng/ml) were important risk factors of disease severity; though delay in treatment and strain type (Boryong, Taguchi, or Kanda/Kawasaki) did not contribute to disease severity. Therapeutic and follow-up data were available In 17 patients with scrub typhus associated HLH, ten of them received oral antibiotics in the form of doxycyclin and/or clarithromycin/minocyclin; six patients received immunotherapy in addition to oral antibiotic therapy (two of them used HLH-2004), and one patient refused any definitive therapy.

Barring two patients (one with residual neurological impairment, and other with fatal outcome), all 15 had a dramatic recovery from their illness without any residual impairment.

Though the HLH protocol has been well established in the management of primary HLH, its utility in the setting of secondary HLH has been controversial. High ferritin level has been reported to be a diagnostic and prognostic marker in patients with HLH, and a rapid rate of fall of ferritin levels following therapy initiation associated with decreased mortality. However, Park et al. in their cohort of 23 patients with secondary HLH found that high fibrinogen at the time of diagnosis, not the rate of decline in ferritin, was associated with prolonged survival. Furthermore, in patients with severe disease and/or associated sepsis or multiple organ failure at the time of diagnosis, it may be difficult to use cytotoxic agents such as etoposide. In such circumstances, immunosuppression with corticosteroids and/or cyclosporine remains the foundation of early management as it can control systemic inflammation. In view of the limited number of cases of HLH at our institute; etoposide has not been widely used; hence limiting our experience. A very high ferritin (>30, 000 ng/ml), in conjunction with other criteria, was highly characteristic of HLH in one of our patients (case 1). During the course of her illness, she developed MODS secondary to sepsis and DIC (prolonged PT, aPTT, and increased fibrin degradation product) (Table 1). She was managed initially with vasopressor drugs, high-dose corticosteroids, and intravenous broad-spectrum antibiotics. Doxycyclin was added following the serological diagnosis of scrub typhus. Once her clinical conditions improved, etoposide was added in consultation with hematologist; however, it was later withdrawn after restoration of normal hematological parameters.

**Summary.** HLH though rare, should be considered in severe cases of scrub typhus especially if associated with cytopenias, liver dysfunction, and coagulation abnormalities. Furthermore, wherever possible, a diagnosis of primary HLH should always be excluded in these cases by appropriate mutation analysis studies. As observed in our three patients and supported by available literature, early diagnosis and initiation of definitive antibiotic therapy may completely reverse the clinical course of the disease. Further studies are needed to understand whether an immunosuppressive and/or immunomodulator therapy such as treatment with corticosteroids, etoposide or cyclosporine could be beneficial in those cases which do not respond promptly to tetracycline therapy.
Author Contribution. Authors AB and SP did the conceptual design, collection, acquisition, and interpretation of the data, writing and editing of the final manuscript. BV provided the patient information and follow-up data. SM did the literature review and collection of the data. SN and RK did the microbiological analysis, and authors SP, RGV, and RK analyzed and edited the manuscript for the intellectual content. All authors agreed to the final content of the manuscript.

References:

1. Rosado FGN, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol 2013; 139:713-727. http://dx.doi.org/10.1093/ajcp/azt140

2. Bode SF, Lehemburg K, Maul-Pavicic A, Vraetz T, Jankia G, Stadl U, Ehl S. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res Ther 2012; 14(3):213. DOI: 10.1186/ar3843. http://dx.doi.org/10.1186/ar3843

3. Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol 2010; 6: 137–154. http://dx.doi.org/10.1586/eci.09.58

4. Roupheal NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated with hemophagocytic syndrome. Lancet Infect Dis 2007; 7:814-822. http://dx.doi.org/10.1016/S1473-3099(07)70290-6

5. Casco A, Giordano S, Dorigo S, Venezia S, Iaria C, Zino O. Hemophagocytic syndrome and ricketsial diseases. J Med Microbiol 2011; 60:537-542. http://dx.doi.org/10.1099/mnj.0.05283-0. PMID:21163825

6. Henter JL, Horne AC, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124-131. http://dx.doi.org/10.1002/pbc.21039

7. Ho C, Yao X, Tian L, Li FY, Podoltev N, Xu ML. Macrophage activation syndrome in a case of severe leptospirosis. Trop Doct 2010; 40:249-250. http://dx.doi.org/10.3947/tropmed.2010.00536

8. Diwan AG, Shewale R, Iyer SR, Iyer KP. Poor correlation with disease probability. Am J Clin Pathol 2013; 139:25327097

9. Goswami D, Hing A, Das A, Lyngdoh M. Scrub typhus associated severe hemophagocytic lymphohistiocytosis. Acta Trop 2007; 103:641-645. http://dx.doi.org/10.1016/j.actatropica.2007.06.003

10. Kamarasu K, Malathi M, Rajagopal V, Subramani K. Distribution of spotted fevers and typhus fever in Tamil Nadu. Indian J Med Res 1983; 32 (5):1101-1107. PMID:6414421

11. Kim HW, Choo BS, Kim JH, Shin YM, Lee SJ, Kim SR, Jun JB. A case of death due to hemophagocytic lymphohistiocytosis accompanied by scrub typhus. Infect Chemother 2010; 42 (4):266-270. http://dx.doi.org/10.3947/ic.2010.42.4.266

12. Gopal GK, Anugrah C, Boorugu H. Scrub typhus associated macrophage activation syndrome. Trop Doct 2010; 40:249-250. http://dx.doi.org/10.1085/tid.2010.0056

13. Valsalan R, Kosaraju K, Sohanlal T, Prem Kumar PS. Hemophagocytic in scrub typhus. J Postgrad Med 2010; 56 (4):301-302.

14. Premaratna R, Williams HS, Chandrasena TG, Rajapakse RP, Kularatna SA, de Silva HJ. Unusual pancytopenia secondary to haemophagocytosis syndrome in rickettsioses. Trans R Soc Trop Med Hyg 2009; 103: 961-963. http://dx.doi.org/10.1016/j.trstmh.2009.04.003

15. Miyakawa K, Obiugi K, Kuriyama C, Sugahara S, Kikuchi A, Ohta M. Tsutsugamushi disease with hemophagocytosis complicated by parvovirus B19 infection. Nippon Naika Gakkai Zashi 2006; 95:2544-2546. http://dx.doi.org/10.2169/naika.95.2544

16. Takami A, Yamauchi H, Asakura H, Ishiyama K, Nakao S. Tsutsugamushi disease (scrub typhus)-associated hemophagocytic syndrome. Int J Hematol 2002; 75 (3):337-338. http://dx.doi.org/10.1002/jh.993

17. Wada M, Yamane Y, Tsunomori M, Kato Y. Tsutsugamushi disease, associated hemophagocytic syndrome. Rinsho Kenkyu 2001; 78:1173-1176.

18. Chen YC, Chao TY, Chin SC. Scrub typhus associated hemophagocytic syndrome. Infection 2000; 28:178-179. PMCID:PMC10505876

19. Iwasaki H, Hashimoto K, Takada N, Nakayama T, Ueda T, Nakamura T. Fulminant Rickettsia tsutsugamushi infection associated with haemophagocytic syndrome. Lancet 1994; 343:1236-1238.

20. Kobayashi T, Takezawa H, Hiroshima K, Uruma T, Enokihara H, Okuyama A. A case of new type scrub typhus (tsutsugamushi disease) presenting with acute respiratory failure and hemophagocytic syndrome. Jpn J Thor Dis 1992: 30:447-452.

21. Paris DH, Day NPJ. Tropical Rickettsial Infections. In: Farrar J, Hotez P, Junghanss T, Kang G, Laloo D, White NJ (editors). Manson's Tropical Diseases: Expert Consult Online. 23rd edition, ELSEVIER, 2014. China. http://dx.doi.org/10.1016/B978-0-7020-5101-2.00003-6

22. Sahni SK, Rydkin E. Host cell interactions with pathogenic Rickettsia species. Future Microbiol 2009; 4:323-339. http://dx.doi.org/10.2217/fmb.09.66

23. Iwasaki H, Takada N, Nakamura T, Ueda T. Increased levels of macrophage colony stimulating factor, gamma interferon and tumour necrosis factor alpha in sera of patients with Orientia tsutsugamushi infection. J Clin Microbiol 1997, 35: 3320-3322. PMID:9399546 PMCID:PMC230174

24. Ozen S, Dai A, Coskun E, Oztuuzcu S, Ergun S, Aktekin E, Yavuz S, Bay A. Importance of hyperbilirubinemia in differentiation of primary and secondary hemophagocytic lymphohistiocytosis in pediatric cases. Medit J Hematol Infect Dis 2014; 6: e2014067. http://dx.doi.org/10.4084/mjh.2014.067

25. Brown GN, Shiraj A, Rogers C, Groves MG. Diagnostic criteria for scrub typhus: probability values for immunofluorescent antibody and Proteus OXK agglutinin titres. Am J Trop Med Hyg 1983; 32 (5):510-513. PMID:7044471

26. Kamarasu K, Malathi M, Rajagopal V, Subramani K. In: Mageedheesharamany D, Mathai E. Serological evidence for wide distribution of spotted fevers and typhus fever in Tamil Nadu. Indian J Med Res 2007; 126:128-130. PMID:17932437

27. Batra HV. Spotted fever and typhus fevers in Tamil Nadu. Indian J Med Res 2007; 126:101-103. PMID:17932432

28. Baksdi, Singhpal P, Mahajan SK, Subramaniyan P, Tutela U, Batra HV, et al. Development of a real-time PCR assay for the diagnosis of scrub typhus cases in India and evidence of the prevalence of new genotype of O. tsutsugamushi. Acta Trop 2007; 104:63-71. http://dx.doi.org/10.1016/j.actatropica.2007.07.013

29. Prakash JA, Reller ME, Batar N, Dumler JS. Assessment of a quantitative multiplex 5' nuclease real-time PCR for spotted fever and typhus group rickettesios and Orientia tsutsugamushi. Clin
35. Yasunaga H, Horiguchi H, Kuwabara K, Hashimoto H, Matsuda S. Delay in tetracycline treatment increases the risk of complications in Tsutsugamushi disease: data from the Japanese Diagnosis Procedure Combination database. Intern Med. 2011; 50:37-42. http://dx.doi.org/10.2169/internalmedicine.50.4220 PMID:21212571

36. Park SW, Lee CS, Lee CK, Kwak YG, Moon C, Kim BN, et al. Severity predictors in eschar-positive scrub typhus and role of serum osteopontin. Am J Trop Med Hyg 2011; 85:924-930. http://dx.doi.org/10.4269/ajtmh.2011.11-0134 PMID:22049051 PMCID:PMC3205643

37. Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 2011; 56:154-155. http://dx.doi.org/10.1002/pbc.22774 PMID:20842751 PMCID:PMC3444147

38. Park HS, Kim DY, Lee JH, Lee BH, Kim SD, Park YH, et al. Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: an analysis of treatment outcome and prognostic factors. Ann Hematol 2012; 91:897-904. http://dx.doi.org/10.1007/s00277-011-1380-3 PMID:22147006